GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: VVUS
Buy $2.80

Vivus, Inc. (NASDAQ: VVUS) upgraded to Buy with price target $2.80 by WallachBeth

Thursday,  Nov 5, 2015  8:25 AM ET by Dave Ficere

WallachBeth upgraded Vivus, Inc. (NASDAQ: VVUS) to Buy with price
target $2.80. Previously WallachBeth rated Hold with price target $8 Vivus, Inc. (NASDAQ: VVUS) on 02/25/2014, when the stock price was $5.89.

Vivus, Inc. is a leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. They develop and market the product MUSE and the medical device ACTIS, two innovations in the treatment of erectile dysfunction. The company has partnered with Abbott Laboratories for the international marketing and distribution of its male erectile dysfunction products. VIVUS also has research and development programs in premature ejaculation and erectile dysfunction. (Company Press Release)

WallachBeth



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy